Abstract The 7th Ammendment to the Cosmetics Directive of the European Commission (Directive 76/ 768/EEC2) bans the marketing of cosmetics containing animal-tested ingredients since March 2009. Excepted are only tests for repeated dose toxicity, for which the animal ban will come into effect by 2013. One major concern for cosmetics, i.e. the risk of containing skin (contact) sensitizers, has in the past been addressed almost exclusively by animal testing. It is this problem attracting the central interest of the integrated research project Sens-it-iv (Novel Testing Strategies for in vitro Assessment of Allergens, http://www.sens-it-iv.eu), funded by the EC within framework 6 since October 2005. Here, the 28 Sens-it-iv partners from 10 European States present the 5 most promising types of in vitro assays selected for further refinement. These are: (1) a human epidermal equivalent (EE) model to rank contact allergens according to their sensitizing potency, (2) identification of contact sensitizers, including prohaptens, through intracellular production of IL-18 by the human keratinocyte cell line NCTC 2544, (3) determination of activation markers such as CD86, CD54 and most prominently CXCL8 (IL-8) on/in dendritic cell lines, (4) contact sensitizer-specific migration of MUTZ Langerhans cells towards the chemokine CXCL12, and (5) the allergen-specific activation and proliferation of naïve human T cells. Ongoing genomic and proteomic experiments are in the process of identifying larger sensitizer-specific biological marker signatures to be integrated into the above assays. We hope to supply the European control agencies with a basis for further validation of in vitro assays by the end of 2010.
, entitled Novel Testing Strategies for in vitro Assessment of Allergens (http:// www.sens-it-iv.eu). In vitro methods, despite persisting difficulties to completely simulate an in vivo immune system, have the advantage of circumventing interspecies differences by concentrating exclusively on human cell material. However, as yet validated in vitro alternatives are lacking, raising questions about the future safety of cosmetics. While final answers to this question have to come from national and international regulatory authorities, the scientific basis is to be laid by basic and applied research, not last within the Sens-it-iv consortium. It's 28 partners from academia, industry and special interest organizations focus on the in vitro identification of both, respiratory and skin sensitizers, but in the context of cosmetics we will here concentrate on our work concerning skin sensitization.
2 The Sens-it-iv concept Sens-it-iv divides its efforts into a science (basic) and a technology (applied) module (Fig. 1) . During the These activities are divided into nine work packages (WP) with WP1 laying the grounds by providing standardized samples and handling procedures of a list of tutorial chemicals, including respiratory and skin sensitizers, irritants and controls (list available under http://www.sens-it-iv.eu). WP2 and WP3 address the different cell types involved in sensitization as well as their mutual interactions, and WPs 4-6 deal with identifying new markers or metabolic pathways, respectively. The most promising assays were transferred into WP8 of the technology module to select the best cell lines and assure reproducibility between different laboratories, and those tests will be discussed below. WP progress is monitored in monthly newsletters under http://www.sens-it-iv.eu.
Skin sensitization in vivo and corresponding predictive in vitro assays
The major steps in the sensitization for contact sensitivity (Karlberg et al. 2008 ) are indicated in Fig. 2 . Chemical allergens after penetration of the stratum corneum bind either directly (haptens) or upon metabolic transformation (pro-haptens) to proteins in the epidermis. Uptake and processing of these modified proteins by epidermal Langerhans cells (LC) is followed by maturation and migration of LC towards the draining lymph node where they activate allergen-specific T cells. The Sens-it-iv approach has dissected this process into several assays, which are also indicated in Fig. 2 . The first one mimics the penetration of the stratum corneum and general irritation of epidermal cells. The second refers to sensitizer-specific responses of epidermal keratinocytes. Tests of type number 3 study the induction of maturation markers on dendritic cells (DC) and corresponding human cell lines, and test number 4 addresses the induction of LC migration. Tests 5 and 6, finally, deal with activation and proliferation of T cells specific for individual sensitizing chemicals. While the latter assays are by nature not made to screen large panels of chemicals, they will be particularly helpful in determining the immunological responsiveness of humans to selected allergens.
The EE potency assay
To determine the allergenic potency of chemicals we developed a 3-dimensional epidermal-equivalent model (EE), which can be constructed from foreskin keratinocytes (Spiekstra et al. 2009 ). The great advantage of this model is that chemicals, independent of their solubility in water may be topically applied on the very same type of filter discs used in human patch testing. The readout is metabolic cell activity by the MTT color reaction and calculation of EC 50 values (i. e. the concentration leading to 50% reduction of metabolic activity). This assay cannot differentiate irritants from allergens. However, when selectively applied to sensitizers identified by any of the other assays below, the majority of EC 50 values correlates well with EC3 data derived in vivo by LLNA testing (Fig. 3) , allowing a classification into strong, intermediate and weak sensitizers. Interestingly, none of the respiratory sensitizers tested so far was active in this assay (Spiekstra et al. 2009 ).
Interleukin 18 (IL-18) production by keratinocytes
Several years ago van Och et al. (2005) reported that human keratinocytes responded to sensitizers by increased production of IL-18. In our current view this may reflect a cleavage of inactive IL-18 precursor via activation of inflammasome located caspase 1 (Martinon et al. 2009 ). Determining intracellular IL-18 in the human keratinocyte cell line NCTC 2544 (Corsini et al. 2009 ) we now established an assay, which correctly detected all contact sensitizers of the Sens-it-iv tutorial chemicals (including the prohaptens eugenol, isoeugenol, cinnamic alcohol and paraphenylenediamine), and neither reacted to irritants nor to respiratory sensitizers (for examples see Fig. 4) . A research proposal to pre-validate this approach is currently being submitted to ZonMW, The Netherlands.
Maturation markers on dendritic cells
Human dendritic cells can be prepared from peripheral blood monocytes (MoDC) in various maturation states. However, besides restricted lifetime and differences between individual donors also interlaboratory variation in the preparations may be significant. Established DC-like human cell lines such as THP-1, U937 or MUTZ-3 may overcome some of these problems (dos ), but on the other hand are even less likely to completely resemble all properties of DCs in vivo. A genomic comparison of different DCs and DC lines revealed significant differences in gene expression between all these cells, but identified MUTZ-3 as the cell line of relative closest similarity to in vivo conditions (Borrebaeck et al. unpublished) . This and the fact that depending on culture conditions MUTZ-3 cells may be obtained in a variety of DC-typical maturation states, including LClike properties, made MUTZ-3 cells to the preferred DC line in our studies. Nevertheless, many experiments also include THP-1 or U937 cells (Python et al. 2009 ) and an ongoing ring trial in different laboratories compares their suitability in our various assays.
A number of sensitizer-specific maturation markers on DCs have been described such as the membrane proteins CD86 and CD54 (Python et al. 2009 ), the signaling protein p38 (Mitjans et al. 2008) , or the secretion of interleukin 8 (IL-8, CXCL8) (Toebak et al. 2009) , with the latter one found to be among the most promising in our hands. Figure 5 shows representative examples for IL-8 responses by MUTZ-3 cells to three different sensitizers and three non-sensitizers. (Corsini et al. 2009 
LC/DC migration assay
To simulate hapten-induced migration of LC from the epidermis to the dermis, a dual chamber experiment was designed. Fluorescently labeled (CSFE) MUTZ-LC in the upper compartment of a well will migrate through a porous filter toward fibroblasts growing on the bottom of the lower chamber where they may be collected and quantified. This migration depends on two fibroblast-derived chemokines, i.e. CXCL12 (Ouwehand et al. 2008 ) and CCL5 (manuscript submitted). Replacement of fibroblasts in the lower chamber by either of the two chemokines effectively retains this directed mobility. Pre-treatment of MUTZ-LC with sensitizers, but not with irritants induces the expression of a CXCL12 receptor and, hence, enhances migration towards CXCL12 without affecting CCL5 dependent migration. For every chemical the index of migration directed towards CXCL12 versus that directed towards CCL5 can be determined. An index of CXCL12:CCL5 [ 1, therefore, indicates sensitizers, values \ 1 non-sensitizers.
T cell priming assay
The final step of the sensitization phase in contact dermatitis is the activation of naïve T cells in the local lymph node. This step creates the remarkable structural specificity in the eventual elicitation phase by selecting and activating a minute fraction within the pool of available T cells. Each of these few cells carries a different, though functionally similar T cell antigen receptors (TCR) allowing a complementary fit to complexes of hapten-modified self-peptides and self-MHC molecules on the surface of DC or other antigen presenting cells (Weltzien et al. 1996; Martin 2004 ).
Our in vitro T cell priming assay employs MoDCs and sorted naïve T cells depleted of the CD25
? regulatory (suppressive) subpopulation of the same donor. MoDCs when modified by direct interaction with haptens or alternatively with hapten-protein adducts in co-culture drive hapten-specific T cells into proliferation and differentiation to produce interleukins such as interferon gamma (IFN-g) . Combination with a polyclonal T cell amplification step (Geiger et al. 2009 ) before the addition of specific allergen can significantly increase the sensitivity of the system and allows for frequency determination of T cells of extremely rare specificities as well as for isolation and functional/genetical analysis of allergen-specific T cell clones.
As mentioned above, such assays may yield valuable information in situations not satisfactory clarified by other tests, while clearly not being developed for high throughput screening.
''-Omics'' Technologies
All assays described above make use of maximally two or three marker molecules. Given the large number of potentially sensitizing chemicals and the different routes of their interaction with the immune system, significantly larger ''signatures'' of biological markers of allergenic stimulation may be required for effective risk assessment. Large genomic and proteomic data sets of allergen-and control-treated DCs and keratinocytes, partially obtained in parallel from the same experiments, are in the process of being analysed. Preliminary results from both groups of data reveal encouraging marker separations into sensitizer, irritant or control specific clusters (Figs. 6,  7) . The time-lag between assay performance and the eventual supply of additional indicative markers has been bridged by freezing culture supernatants and RNA samples from most test models under study. In this way all materials may later be assayed for newly defined markers on RNA and/or protein level.
Conclusions
The EU ban of animal experiments for risk assessment of cosmetics by the 7th Amendment to the Cosmetics Directive has induced widespread activities in search for in vitro alternatives. There is general consensus that a combination of several functionally distinct human-based in vitro strategies can be successful and may eventually even surpass the accuracy of animal experiments. Following this route, several mechanistically relevant and promising test-strategies have been developed within the Sens-it-iv project and are being further refined. We see realistic chances to refine some of these assays to the stage where they can be formally evaluated and validated. The timing, however, to get these new technologies accepted by regulatory and legislative bodies lies outside the influence of Sens-it-iv. In that sense an answer to the original question concerning the future safety of cosmetics may depend on necessary interim solutions enforced by regulatory authorities. 
